More on FBRX

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-5.2% Growth)
- Ratings (4.5 Score)

Upcoming Events

- Earnings (8/17/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Forte Biosciences (NQ:FBRX)
Delayed: 76.65 +0.15 (0.20%)
Prev. Close $76.50  
Open$76.50 
52 Wk High$ 
52 Wk Low$ 
Day High$76.68 
Day Low$76.50 
P/E N/A  
EPS$ 
Volume2,571,080 

Friends, Peers and Foes (?): APLD, NUAI, STAA, STZ, PEP (more...)

Jul 28, 2026 03:34 AM Barclays Downgrades Forte Biosciences Inc. (FBRX) to Equalweight
Jul 27, 2026 11:30 AM Brookline Capital Markets Downgrades Forte Biosciences Inc. (FBRX) to Hold
Jul 27, 2026 11:29 AM Evercore ISI Downgrades Forte Biosciences Inc. (FBRX) to In Line
Jul 27, 2026 08:14 AM TD Cowen Downgrades Forte Biosciences Inc. (FBRX) to Hold
Jul 27, 2026 01:00 AM argenx to acquire Forte Biosciences for $2.2 billion
Jul 27, 2026 01:00 AM argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
Jul 21, 2026 03:47 AM Barclays Starts Forte Biosciences Inc. (FBRX) at Overweight
Jul 9, 2026 08:39 AM Enovix, Forte Biosciences rally premarket; PepsiCo slips
Jul 9, 2026 08:02 AM Forte Biosciences FB102 shows vitiligo improvement in phase 1b trial
Jul 9, 2026 08:00 AM FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
View All Articles

Entities mentioned with FBRX

View All Entities